Stifel analyst Annabel Samimy raised the firm’s price target on Ligand (LGND) to $220 from $195 and keeps a Buy rating on the shares. Consistently exceeding expectations, Ligand posted Q3 revenues of $86.9M an adjusted EPS of $3.09, reflecting a strong win on project financing and diversified royalty portfolio with growth drivers that consistently beat consensus, the analyst tells investors in a research note. The firm added the the company continues to execute across deal types in a capital-hungry financing environment.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Ligand price target raised to $220 from $175 at Benchmark
- Ligand price target raised to $275 from $250 at Oppenheimer
- Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer
- Ligand Pharmaceuticals Reports Strong Q3 Results and Raises Guidance
- Ligand price target raised to $231 from $206 at H.C. Wainwright